Based on this preclinical and clinical data, we hypothesized that combination therapy with a dual mTOR/pan-PI3 K inhibitor, gedatolisib, and the PARPi, talazoparib, may be effective in breast cancer patients with a gBRCA1/2 m and in patients with BRCA1/2-wildtype TNBC. The gene discussed is BRCA1; the disease is breast cancer.